Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

2(28.6%)

Phase 1

2(28.6%)

Phase 3

2(28.6%)

N/A

1(14.3%)

7Total

Phase 2(2)

Phase 1(2)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01376700Phase 3Terminated

Early Prophylaxis Immunologic Challenge (EPIC) Study

Role: collaborator

NCT01504347Phase 1Completed

Phase 1/2 Lyme Vaccine Study

Role: collaborator

NCT01599819Phase 1Completed

BAX 855 Dose-Escalation Safety Study

Role: collaborator

NCT01382329Phase 2Completed

H5N1 Vaccine Study in Japanese Adults

Role: collaborator

NCT01911754Phase 3Completed

Japanese Pediatric H5N1 Vaccine Study

Role: collaborator

NCT01244425Phase 2Completed

Fibrin Sealant VH S/D 500 S-apr in Hepatic Resection

Role: collaborator

NCT01637025Not ApplicableCompleted

Oxidized Cellulose hEmostAsis evaluatioN

Role: collaborator

All 7 trials loaded